Non-small cell lung cancer: an update on emerging EGFR-targeted therapies

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2024-04-04 DOI:10.1080/14728214.2024.2331139

Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, Laura Fabbri, Renata Seminerio, Alessandro Di Federico, Eleonora Gariazzo, Silvia Costabile, Giulio Metro

引用次数: 0

Abstract

Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies’ field of action to earlier st...

查看原文本刊更多论文

非小细胞肺癌：表皮生长因子受体靶向疗法的最新进展

目前对表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）的研究重点是耐药性和不常见突变的管理，以及将靶向疗法的作用范围扩大到早期阶段的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.